Related Experiment Video
Updated: Jun 2, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Prognostic significance of smac/DIABLO in endometrioid endometrial cancer
Bozena Dobrzycka1, Slawomir J Terlikowski, Piotr S Bernaczyk
1Department of Obstetrics, Gynecology and Obstetrics / Gynecological Care, Medical University of Bialystok, Poland. bdobrzycka@gmail.com
Abstract:
Apoptosis may occur via a death receptor-dependent or independent (mitochondrial) pathway. The mitochondrial pathway is regulated by small molecules, such as smac/Diablo, which activates caspase cascades. This study examined smac/DIABLO expression in 76 patients with endometrioid endometrial cancers. Presence of smac/DIABLO was quantified by Western blot analysis using nonfixed fresh frozen tissues. Its appearance was found in 55 (72%) of examined tumors. Smac/DIABLO expression significantly correlated with tumor grade (p<0.001). Patients with positive smac/DIABLO tumors had a longer disease-specific survival when compared with those with negative tumors in the 10-year follow-up (p=0.043). The study demonstrated that negative smac/DIABLO expression was a poor prognostic sign.
Insights
Smac/DIABLO expression in endometrial cancer indicates a better prognosis. Negative Smac/DIABLO (second mitochondria-derived activator of caspases) expression is a poor prognostic sign, with positive tumors showing longer survival.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Pathways
Background:
- Apoptosis, or programmed cell death, can proceed through receptor-dependent or independent (mitochondrial) pathways.
- The mitochondrial pathway is modulated by proteins like Smac/DIABLO (second mitochondria-derived activator of caspases), which promote caspase activation and cell death.
- Endometrioid endometrial cancer is a common gynecological malignancy, and understanding its molecular drivers is crucial for prognosis.
Purpose of the Study:
- To investigate the expression of Smac/DIABLO in endometrioid endometrial cancer tissues.
- To determine the correlation between Smac/DIABLO expression and clinicopathological features, including tumor grade.
- To evaluate the prognostic significance of Smac/DIABLO expression on disease-specific survival.
Main Methods:
- Western blot analysis was employed to quantify Smac/DIABLO protein levels.
- The study utilized nonfixed, fresh-frozen tissue samples from 76 patients diagnosed with endometrioid endometrial cancer.
- Statistical analyses were performed to assess correlations and survival outcomes.
Main Results:
- Smac/DIABLO expression was detected in 55 out of 76 (72%) examined tumors.
- A significant correlation was observed between Smac/DIABLO expression and tumor grade (p<0.001).
- Patients with Smac/DIABLO-positive tumors exhibited significantly longer disease-specific survival compared to those with negative tumors over a 10-year follow-up period (p=0.043).
Conclusions:
- Negative Smac/DIABLO expression is identified as a significant indicator of poor prognosis in endometrioid endometrial cancer.
- The presence of Smac/DIABLO is associated with improved disease-specific survival, suggesting a potential role in predicting patient outcomes.
- These findings highlight Smac/DIABLO as a relevant biomarker in endometrioid endometrial cancer management.